{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:33:05Z","timestamp":1786984385565,"version":"build-2736575974"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Louisiana Board of Regents Research Competitiveness Award","award":["LEQSF-RD-A-13"],"award-info":[{"award-number":["LEQSF-RD-A-13"]}]},{"DOI":"10.13039\/100006952","name":"Louisiana Board of Regents","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006952","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Louisiana Vaccine Center"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"crossref","award":["P20RR021970"],"award-info":[{"award-number":["P20RR021970"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"crossref","award":["P20GM103501"],"award-info":[{"award-number":["P20GM103501"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"crossref","award":["P30GM106392"],"award-info":[{"award-number":["P30GM106392"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["R01AI112402"],"award-info":[{"award-number":["R01AI112402"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"crossref","award":["U54GM104940"],"award-info":[{"award-number":["U54GM104940"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Louisiana Clinical and Translational Science Center"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.antiviral.2016.05.009","type":"journal-article","created":{"date-parts":[[2016,5,15]],"date-time":"2016-05-15T10:01:31Z","timestamp":1463306491000},"page":"13-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Development and evaluation of a host-targeted antiviral that abrogates herpes simplex virus replication through modulation of arginine-associated metabolic pathways"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5271-9840","authenticated-orcid":false,"given":"Maria Dulfary","family":"Sanchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto C.","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0269-4646","authenticated-orcid":false,"given":"Timothy P.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2016.05.009_bib1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1099\/0022-1317-12-3-249","article-title":"The effect of arginine deprivation on the replication of vaccinia virus","volume":"12","author":"Archard","year":"1971","journal-title":"J.\u00a0General Virol."},{"key":"10.1016\/j.antiviral.2016.05.009_bib2","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1097\/01.WCB.0000080651.64357.C6","article-title":"L-arginine levels in blood as a marker of nitric oxide-mediated brain damage in acute stroke: a clinical and experimental study","volume":"23","author":"Armengou","year":"2003","journal-title":"J.\u00a0Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.antiviral.2016.05.009_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00075197-200303000-00012","article-title":"Arginine availability, arginase, and the immune response","volume":"6","author":"Bansal","year":"2003","journal-title":"Curr. Opin. Clin. Nutr. Metabolic Care"},{"key":"10.1016\/j.antiviral.2016.05.009_bib4","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1128\/AAC.46.6.1766-1772.2002","article-title":"Potent in\u00a0vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293","volume":"46","author":"Betz","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.05.009_bib5","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00705-007-0964-7","article-title":"Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture","volume":"152","author":"Biswas","year":"2007","journal-title":"Archives Virol."},{"key":"10.1016\/j.antiviral.2016.05.009_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/0008-5472.CAN-06-1945","article-title":"Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in\u00a0vitro and in\u00a0vivo proliferation of human hepatocellular carcinoma through arginine depletion","volume":"67","author":"Cheng","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2016.05.009_bib7","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1128\/AAC.42.4.868","article-title":"Survey of resistance of herpes simplex virus to acyclovir in northwest England","volume":"42","author":"Christophers","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.05.009_bib8","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1073\/pnas.77.4.2265","article-title":"Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1","volume":"77","author":"Coen","year":"1980","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2016.05.009_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jcv.2011.08.003","article-title":"Current management and recommendations for access to antiviral therapy of herpes labialis","volume":"53","author":"Cunningham","year":"2012","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.antiviral.2016.05.009_bib10","doi-asserted-by":"crossref","first-page":"859","DOI":"10.7326\/0003-4819-107-6-859","article-title":"Drugs five years later: acyclovir","volume":"107","author":"Dorsky","year":"1987","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2016.05.009_bib11","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/606028","article-title":"Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis","volume":"200","author":"Duan","year":"2009","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.05.009_bib12","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-76-3-112-6-416","article-title":"Herpes simplex virus resistant to acyclovir. A study in a tertiary care center","volume":"112","author":"Englund","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2016.05.009_bib13","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1517\/13543784.15.7.815","article-title":"Pegylated arginine deiminase: a novel anticancer enzyme agent","volume":"15","author":"Feun","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.antiviral.2016.05.009_bib14","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2174\/138161208784246199","article-title":"Arginine deprivation as a targeted therapy for cancer","volume":"14","author":"Feun","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.antiviral.2016.05.009_bib15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/BF01963751","article-title":"Persistent herpes simplex virus infection and mechanisms of virus drug resistance","volume":"8","author":"Field","year":"1989","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2016.05.009_bib16","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/JVI.60.1.286-289.1986","article-title":"Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene","volume":"60","author":"Field","year":"1986","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.05.009_bib17","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/infdis\/169.6.1338","article-title":"Recurrence and resistance patterns of herpes simplex virus following cessation of > or\u00a0= 6 years of chronic suppression with acyclovir. Acyclovir Study Group","volume":"169","author":"Fife","year":"1994","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.05.009_bib18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/AAC.26.3.382","article-title":"Herpes simplex virus mutants resistant to arabinosyladenine in the presence of deoxycoformycin","volume":"26","author":"Fleming","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.05.009_bib19","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1002\/eji.201141683","article-title":"Arginine depletion as a mechanism for the immune privilege of corneal allografts","volume":"41","author":"Fu","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.antiviral.2016.05.009_bib20","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1200\/JCO.2009.26.7765","article-title":"Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma","volume":"28","author":"Glazer","year":"2010","journal-title":"J.\u00a0Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.antiviral.2016.05.009_bib21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMcp013211","article-title":"Clinical practice. Herpes zoster","volume":"347","author":"Gnann","year":"2002","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2016.05.009_bib22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1099\/0022-1317-3-1-143","article-title":"Effect of withdrawal of arginine and other amino acids on the synthesis of tumour and viral antigens of SV 40 virus","volume":"3","author":"Goldblum","year":"1968","journal-title":"J.\u00a0General Virol."},{"key":"10.1016\/j.antiviral.2016.05.009_bib23","first-page":"263","article-title":"Effect of arginine deficiency on the reproduction of human cytomegalovirus","volume":"22","author":"Gonczol","year":"1975","journal-title":"Acta Microbiol. Acad. Sci. Hung."},{"key":"10.1016\/j.antiviral.2016.05.009_bib24","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1128\/JVI.77.3.2282-2286.2003","article-title":"High-frequency phenotypic reversion and pathogenicity of an acyclovir-resistant herpes simplex virus mutant","volume":"77","author":"Griffiths","year":"2003","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.05.009_bib25","doi-asserted-by":"crossref","first-page":"8230","DOI":"10.1128\/JVI.00686-08","article-title":"The high prevalence of herpes simplex virus type 1 DNA in human trigeminal ganglia is not a function of age or gender","volume":"82","author":"Hill","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.05.009_bib26","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1086\/515375","article-title":"Recurrent acyclovir-resistant herpes simplex in an immunocompromised patient: can strain differences compensate for loss of thymidine kinase in pathogenesis?","volume":"178","author":"Horsburgh","year":"1998","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.05.009_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.virusres.2012.05.010","article-title":"HSV-2 inhibits type-I interferon signaling via multiple complementary and compensatory STAT2-associated mechanisms","volume":"167","author":"Kadeppagari","year":"2012","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2016.05.009_bib28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00414614","article-title":"The significance of the arginine and arginase of tears in experimentally-induced herpes simplex corneae. Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie","volume":"209","author":"Kahan","year":"1979","journal-title":"Albrecht von Graefe\u2019s Archive Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.antiviral.2016.05.009_bib29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1053\/j.spid.2005.06.007","article-title":"Herpes simplex virus infections in neonates and early childhood","volume":"16","author":"Kimberlin","year":"2005","journal-title":"Seminars Pediatr. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.05.009_bib30","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm0402-392","article-title":"New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease","volume":"8","author":"Kleymann","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2016.05.009_bib31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00007435-199004000-00009","article-title":"The frequency of unrecognized type 2 herpes simplex virus infection among women. Implications for the control of genital herpes","volume":"17","author":"Koutsky","year":"1990","journal-title":"Sex. Transm. Dis."},{"key":"10.1016\/j.antiviral.2016.05.009_bib32","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1086\/430612","article-title":"Recurrent antiviral-resistant genital herpes in an immunocompetent patient","volume":"192","author":"Kriesel","year":"2005","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.05.009_bib33","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1182\/blood.V99.3.1085","article-title":"Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation","volume":"99","author":"Langston","year":"2002","journal-title":"Blood"},{"issue":"Suppl.\u00a05","key":"10.1016\/j.antiviral.2016.05.009_bib34","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.1086\/422364","article-title":"Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients","volume":"39","author":"Levin","year":"2004","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"10.1016\/j.antiviral.2016.05.009_bib35","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.3945\/jn.111.148197","article-title":"Reference intervals for plasma L-arginine and the L-arginine:asymmetric dimethylarginine ratio in the Framingham offspring cohort","volume":"141","author":"Luneburg","year":"2011","journal-title":"J.\u00a0Nutr."},{"key":"10.1016\/j.antiviral.2016.05.009_bib36","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/biot.201000080","article-title":"The virus as metabolic engineer","volume":"5","author":"Maynard","year":"2010","journal-title":"Biotechnol. J."},{"key":"10.1016\/j.antiviral.2016.05.009_bib37","doi-asserted-by":"crossref","first-page":"508S","DOI":"10.1093\/ajcn\/83.2.508S","article-title":"Arginine: beyond protein","volume":"83","author":"Morris","year":"2006","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.antiviral.2016.05.009_bib38","doi-asserted-by":"crossref","first-page":"1602S","DOI":"10.1093\/jn\/137.6.1602S","article-title":"Arginine metabolism: boundaries of our knowledge","volume":"137","author":"Morris","year":"2007","journal-title":"J.\u00a0Nutr."},{"key":"10.1016\/j.antiviral.2016.05.009_bib39","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1476-5381.2009.00278.x","article-title":"Recent advances in arginine metabolism: roles and regulation of the arginases","volume":"157","author":"Morris","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.antiviral.2016.05.009_bib40","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2014-09-600643","article-title":"Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target","volume":"125","author":"Mussai","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2016.05.009_bib41","doi-asserted-by":"crossref","first-page":"32583","DOI":"10.1074\/jbc.M114.609453","article-title":"UL52 primase interactions in the herpes simplex virus 1 helicase-primase are affected by antiviral compounds and mutations causing drug resistance","volume":"289","author":"Muylaert","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2016.05.009_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jmv.1890360102","article-title":"Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey","volume":"36","author":"Nugier","year":"1992","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.antiviral.2016.05.009_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0166-3542(97)00054-5","article-title":"Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants","volume":"37","author":"Pelosi","year":"1998","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.05.009_bib44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/archinte.163.1.76","article-title":"Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics","volume":"163","author":"Reyes","year":"2003","journal-title":"Archives Intern. Med."},{"key":"10.1016\/j.antiviral.2016.05.009_bib45","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-065X.2008.00608.x","article-title":"Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives","volume":"222","author":"Rodriguez","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.antiviral.2016.05.009_bib46","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1158\/0008-5472.CAN-04-0465","article-title":"Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses","volume":"64","author":"Rodriguez","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.antiviral.2016.05.009_bib47","doi-asserted-by":"crossref","first-page":"21123","DOI":"10.1074\/jbc.M110675200","article-title":"Regulation of T cell receptor CD3zeta chain expression by L-arginine","volume":"277","author":"Rodriguez","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.antiviral.2016.05.009_bib48","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.4049\/jimmunol.171.3.1232","article-title":"L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes","volume":"171","author":"Rodriguez","year":"2003","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.antiviral.2016.05.009_bib49","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0042-6822(67)90128-6","article-title":"An arginine-dependent step in the maturation of type 2 adenovirus","volume":"33","author":"Rouse","year":"1967","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2016.05.009_bib50","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jviromet.2011.10.009","article-title":"Efficient generation and rapid isolation via stoplight recombination of Herpes simplex viruses expressing model antigenic and immunological epitopes","volume":"179","author":"Sanchez","year":"2012","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.antiviral.2016.05.009_bib51","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/cvr\/cvv117","article-title":"Lymphatic vascular integrity is disrupted in type 2 diabetes due to impaired nitric oxide signalling","volume":"107","author":"Scallan","year":"2015","journal-title":"Cardiovasc. Res."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.antiviral.2016.05.009_bib52","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/343739","article-title":"Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review","volume":"186","author":"Smith","year":"2002","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.05.009_bib53","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/0042-6822(69)90193-7","article-title":"Selective failure of protein synthesis in herpesvirus-infected cells deprived of arginine","volume":"38","author":"Spring","year":"1969","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2016.05.009_bib54","series-title":"CLSI. Antiviral Susceptibility Testing: Herpes Simplex Virus by Plaque Reduction Assay; Approved Standard, M33-A","author":"Sweirkosz","year":"2004"},{"key":"10.1016\/j.antiviral.2016.05.009_bib55","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1128\/JB.87.3.609-613.1964","article-title":"Amino acid requirements of herpes simplex virus in human cells","volume":"87","author":"Tankersley","year":"1964","journal-title":"J.\u00a0Bacteriol."},{"key":"10.1016\/j.antiviral.2016.05.009_bib56","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1158\/1078-0432.CCR-14-2610","article-title":"Phase I trial of arginine deprivation therapy with ADI-PEG 20 plus docetaxel in patients with advanced malignant solid tumors","volume":"21","author":"Tomlinson","year":"2015","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.antiviral.2016.05.009_bib57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1475-2867-9-9","article-title":"Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in\u00a0vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in\u00a0vivo and in\u00a0vitro and action upon hepatocellular carcinoma cell (HCC)","volume":"9","author":"Tsui","year":"2009","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.antiviral.2016.05.009_bib58","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jcv.2011.06.009","article-title":"Identification and characterization of acyclovir-resistant clinical HSV-1 isolates from children","volume":"52","author":"Wang","year":"2011","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.antiviral.2016.05.009_bib59","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1517\/14728222.2013.827663","article-title":"The DNA helicase-primase complex as a target for herpes viral infection","volume":"17","author":"Weller","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.antiviral.2016.05.009_bib60","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/spid.2002.29752","article-title":"Herpes simplex virus infection","volume":"13","author":"Whitley","year":"2002","journal-title":"Seminars Pediatr. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.05.009_bib61","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.antiviral.2006.04.002","article-title":"Herpes simplex encephalitis: adolescents and adults","volume":"71","author":"Whitley","year":"2006","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.05.009_bib62","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(02)07681-X","article-title":"Viral encephalitis: familiar infections and emerging pathogens","volume":"359","author":"Whitley","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2016.05.009_bib63","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1099\/0022-1317-39-2-281","article-title":"Amino acid requirement of adenovirus multiplication","volume":"39","author":"Wigand","year":"1978","journal-title":"J.\u00a0General Virol."},{"key":"10.1016\/j.antiviral.2016.05.009_bib64","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00726-008-0210-y","article-title":"Arginine metabolism and nutrition in growth, health and disease","volume":"37","author":"Wu","year":"2009","journal-title":"Amino Acids"},{"key":"10.1016\/j.antiviral.2016.05.009_bib65","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1093\/jn\/130.11.2626","article-title":"Arginine nutrition and cardiovascular function","volume":"130","author":"Wu","year":"2000","journal-title":"J.\u00a0Nutr."},{"issue":"Pt 1","key":"10.1016\/j.antiviral.2016.05.009_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj3360001","article-title":"Arginine metabolism: nitric oxide and beyond","volume":"336","author":"Wu","year":"1998","journal-title":"Biochem. J."},{"key":"10.1016\/j.antiviral.2016.05.009_bib67","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jama.296.8.964","article-title":"Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States","volume":"296","author":"Xu","year":"2006","journal-title":"Jama"},{"key":"10.1016\/j.antiviral.2016.05.009_bib68","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10637-012-9807-9","article-title":"A\u00a0phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma","volume":"31","author":"Yau","year":"2013","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.antiviral.2016.05.009_bib69","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1365-4632.2007.03449.x","article-title":"Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome","volume":"46","author":"Ziyaeyan","year":"2007","journal-title":"Int. J. dermatology"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216302753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216302753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T17:25:31Z","timestamp":1600536331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216302753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":69,"alternative-id":["S0166354216302753"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.05.009","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and evaluation of a host-targeted antiviral that abrogates herpes simplex virus replication through modulation of arginine-associated metabolic pathways","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}